Nuvalent (NASDAQ:NUVL) Rating Increased to Strong-Buy at Sanford C. Bernstein

Posted by George Bondi on May 23rd, 2026

Sanford C. Bernstein upgraded shares of Nuvalent (NASDAQ:NUVL – Free Report) to a strong-buy rating in a research report sent to investors on Thursday,Zacks.com reports.

A number of other research analysts have also commented on the company. Wedbush reaffirmed an “outperform” rating and issued a $125.00 price objective on shares of Nuvalent in a report on Wednesday, April 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvalent in a research report on Tuesday, April 21st. Wells Fargo & Company assumed coverage on shares of Nuvalent in a report on Monday, March 30th. They issued an “overweight” rating and a $116.00 price objective for the company. Cantor Fitzgerald raised their target price on shares of Nuvalent from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Friday, February 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $155.00 price target on shares of Nuvalent in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Nuvalent presently has an average rating of “Moderate Buy” and an average price target of $140.29.

View Our Latest Report on Nuvalent

Nuvalent Stock Up 0.9%

Nuvalent stock opened at $102.12 on Thursday. Nuvalent has a twelve month low of $70.25 and a twelve month high of $113.01. The stock has a market cap of $8.07 billion, a P/E ratio of -16.85 and a beta of 1.15. The company’s 50-day moving average price is $102.18 and its two-hundred day moving average price is $102.76.

Nuvalent (NASDAQ:NUVL – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same quarter in the prior year, the business earned ($1.18) earnings per share. Equities analysts anticipate that Nuvalent will post -5.74 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Deborah Ann Miller sold 5,500 shares of the company’s stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $99.22, for a total transaction of $545,710.00. Following the completion of the sale, the insider owned 59,634 shares of the company’s stock, valued at approximately $5,916,885.48. This represents a 8.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Henry E. Pelish sold 3,093 shares of the company’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $104.48, for a total value of $323,156.64. Following the sale, the insider owned 65,604 shares of the company’s stock, valued at $6,854,305.92. The trade was a 4.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 80,023 shares of company stock valued at $8,235,217 over the last quarter. 5.02% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Nuvalent

A number of hedge funds have recently made changes to their positions in the stock. Candriam S.C.A. boosted its position in Nuvalent by 9.4% in the third quarter. Candriam S.C.A. now owns 329,721 shares of the company’s stock valued at $28,514,000 after buying an additional 28,462 shares in the last quarter. Hudson Bay Capital Management LP acquired a new position in shares of Nuvalent during the third quarter worth $1,297,000. HighVista Strategies LLC lifted its stake in shares of Nuvalent by 84.9% in the 3rd quarter. HighVista Strategies LLC now owns 93,294 shares of the company’s stock valued at $8,068,000 after acquiring an additional 42,834 shares during the last quarter. Aberdeen Group plc lifted its stake in shares of Nuvalent by 115.4% in the 4th quarter. Aberdeen Group plc now owns 165,177 shares of the company’s stock valued at $16,615,000 after acquiring an additional 88,489 shares during the last quarter. Finally, Cantor Fitzgerald L. P. acquired a new stake in shares of Nuvalent during the 3rd quarter valued at $1,946,000. 97.26% of the stock is currently owned by institutional investors and hedge funds.

About Nuvalent

(Get Free Report)

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.